The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics

• Knee osteoarthritis costs the U.S. healthcare system billions of dollars annually, creating growing demand for treatment options that can address cartilage damage before it progresses to more costly joint degeneration.
• Unlike complex cell-based therapies that often require multiple procedures and specialized laboratory processing, Gelrin C from Regentis is a cell-free, off-the-shelf hydrogel designed to fit within existing surgical workflows.
• With approximately 470,000 cartilage repair procedures performed annually in the U.S., Regentis is targeting a multi-billion-dollar market where providers, payers and patients are seeking more practical regenerative solutions.

What begins as a localized cartilage defect can ultimately evolve into a significant clinical and economic challenge. Unlike many tissues in the body, articular cartilage has little ability to regenerate on its own, leaving untreated lesions vulnerable to progressive deterioration that may culminate in osteoarthritis (“OA”).

Historically, healthcare providers have had limited options for addressing cartilage damage before it progresses to more severe joint deterioration. Conventional microfracture procedures are relatively simple and cost-effective but often produce fibrocartilage with limited long-term durability. Meanwhile, cell-based regenerative therapies can involve multiple surgeries, extensive laboratory processing and substantial treatment costs, creating major barriers to widespread adoption.

Today, advances in regenerative medicine are creating new opportunities to address cartilage damage more effectively and efficiently. Among them is Regentis Biomaterials Ltd. (NYSE American: RGNT) Gelrin C, a cell-free, 10-minute procedure of an off-the-shelf hydrogel designed to support cartilage regeneration while avoiding many of the logistical and economic challenges associated with complex multi-stage procedures.

The commercial thesis behind GelrinC is that cartilage repair does not only need better biology. It needs a product architecture that can be adopted. Hospitals need procedures that fit existing operating room workflows. Surgeons need techniques that are practical to learn and repeat. Payers need solutions that do not carry the logistical and financial burden of individualized cell therapy. GelrinC’s off-the-shelf, cell-free, single-stage design directly addresses those adoption barriers.

The Economic Drain of “Wait and See”

When a cartilage defect is ignored or poorly treated, the financial toll quickly multiplies:

The economic consequences of untreated cartilage damage extend far beyond the initial injury. As cartilage defects progress toward osteoarthritis (“OA”), healthcare costs can rise dramatically through ongoing physician visits, imaging, injections, rehabilitation programs and, in many cases, eventual joint replacement procedures. Studies suggest that the lifetime cost of managing a patient who develops knee OA can exceed $140,000, while a large U.S. claims-based analysis estimated that newly diagnosed knee OA patients incur healthcare costs nearly double those of matched controls. Based on prevalence and treatment utilization data, researchers estimated the annual economic burden of knee OA in the United States at approximately $5.7 billion to $15 billion in financial strain. Beyond direct medical expenses, cartilage injuries often affect younger, active individuals, creating additional costs through reduced productivity, workplace absenteeism and disability.

Disrupted Dynamics: How Gelrin C Rewrites the Financial Math

The challenge for healthcare systems has historically been the lack of an ideal middle ground between relatively inexpensive procedures and more complex regenerative approaches. Conventional microfracture techniques are widely used but often ineffective as they result in fibrocartilage that lacks the durability and biomechanical properties of native cartilage. Meanwhile, cell-based therapies can involve multiple surgical procedures, specialized laboratory processing and significantly higher upfront costs, creating barriers for providers, payers and patients alike.

Regentis Biomaterials believes Gelrin C may offer a different approach. The company’s cell-free, off-the-shelf hydrogel is administered in a 10 minute procedure which minimizes trauma while avoiding the logistical complexities associated with harvesting, expanding and reimplanting a patient’s cells. Because the treatment is delivered in a single surgical setting, it has the potential to simplify care pathways while reducing many of the costs traditionally associated with advanced cartilage repair.

The Macroeconomic Reality of a 10-minute Procedure 

The economic rationale is supported by the product’s underlying design. Gelrin C consists of a hydrogel matrix combining polyethylene glycol (“PEG”) and denatured fibrinogen. The material is applied directly to the cartilage defect and cured with ultraviolet light in approximately 90 seconds, forming a solid matrix that conforms to the defect site. Over time, the implant gradually erodes and resorbs as new tissue develops. According to Regentis, clinical studies have demonstrated the formation of hyaline-like cartilage and substantial improvements in pain and function, outcomes that could prove increasingly important as healthcare systems seek solutions capable of addressing cartilage damage before it progresses to more costly degenerative joint disease.

From a health economics standpoint, this changes everything. With an estimated 470,000 annual knee cartilage repair cases in the U.S. representing a $3 billion market, insurers have long resisted covering expensive cell-based treatments. Gelrin C eliminates this friction by offering an economic sweet spot: it scales down the cost of advanced regenerative medicine to a level that is easily absorbed by hospital budgets and insurance frameworks, fundamentally preventing the downstream progression to expensive osteoarthritis.

From a health economics perspective, the appeal of Gelrin C lies in its ability to address a significant unmet need without introducing the complexity typically associated with advanced regenerative therapies. With an estimated 470,000 cartilage repair procedures performed annually in the United States, representing a market opportunity of approximately $3 billion, healthcare providers and payers continue to seek solutions that balance clinical outcomes with economic practicality. By utilizing a cell-free, off-the-shelf approach that integrates into existing surgical workflows, Gelrin C is designed to reduce many of the logistical and cost-related challenges that have historically limited broader adoption of regenerative cartilage repair technologies.

As Regentis Biomaterials advances its commercialization efforts, the company is positioning itself within a large and underserved segment of orthopedic medicine. Gelrin C’s single-step treatment approach, proprietary hydrogel technology and growing body of clinical data differentiate it from both conventional microfracture procedures and more complex cell-based alternatives. Equally important, the technology has been designed to fit within existing healthcare infrastructure, potentially lowering barriers to physician adoption and reimbursement. If Gelrin C continues to demonstrate its ability to support durable cartilage regeneration while maintaining a practical economic profile, Regentis could be well positioned to participate in the growing demand for regenerative solutions aimed at preserving joint health and delaying the progression of osteoarthritis.

For more information, visit the company’s website at www.Regentis.co.il.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai.

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN.

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN